Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study

Marco Ruella, Andrea Riccardo Filippi, Riccardo Bruna, Anna Di Russo, Michele Magni, Daniele Caracciolo, Roberto Passera, Paola Matteucci, Massimo Di Nicola, Paolo Corradini, Guido Parvis, Guido Gini, Attilio Olivieri, Marco Ladetto, Umberto Ricardi, Corrado Tarella, Liliana Devizzi

Research output: Contribution to journalArticle

Abstract

Purpose Rituximab (Rit) therapy added to involved-field radiation therapy (RT) has been proposed as an effective treatment for stage I-II follicular lymphoma (FL). The results of an observational multicenter study on the Rit-RT combination in limited-stage FL are here reported. Methods and Materials Data have been collected from 2 consecutive cohorts of 94 patients with stage I-II FL treated between 1985 and 2011 at 5 Italian institutions. All patients had grade 1-3a FL, a median age of 54 years (range: 25-82). The first 51 patients received RT alone (control group), while the subsequent series of 43 patients received 4 rituximab courses (375 mg/m2, days 1, 8, 15, 22) before RT (Rit-RT). Molecular disease was evaluated by nested bcl-2/IgH PCR or clonal IgH rearrangement was available in 33 Rit-RT patients. Results At a median follow-up of 10.9 years (range: 1.8-22.9), the 10-year progression-free survival (PFS) and overall survival (OS) projections for the whole cohort were 57% and 87.5%, respectively. The 10-year PFS was significantly longer (P

Original languageEnglish
Pages (from-to)783-791
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume94
Issue number4
DOIs
Publication statusPublished - Mar 15 2016

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Fingerprint Dive into the research topics of 'Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study'. Together they form a unique fingerprint.

  • Cite this